ExodusPoint Capital Management LP Buys Shares of 6,816 USANA Health Sciences, Inc. (NYSE:USNA)

ExodusPoint Capital Management LP bought a new stake in USANA Health Sciences, Inc. (NYSE:USNA – Get Rating) during the 3rd quarter, HoldingsChannel reports. The fund bought 6,816 shares of the company’s stock, valued at approximately $382,000.

Several other hedge funds have also recently bought and sold shares of USNA. Vanguard Group Inc. boosted its stake in shares of USANA Health Sciences by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 1,510,852 shares of the company’s stock valued at $120,037,000 after purchasing an additional 12,121 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of USANA Health Sciences by 0.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,431,797 shares of the company’s stock valued at $103,605,000 after purchasing an additional 7,534 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of USANA Health Sciences by 0.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 566,420 shares of the company’s stock valued at $45,002,000 after purchasing an additional 2,390 shares in the last quarter. State Street Corp boosted its stake in shares of USANA Health Sciences by 1.8% in the 1st quarter. State Street Corp now owns 386,877 shares of the company’s stock valued at $30,737,000 after purchasing an additional 6,817 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of USANA Health Sciences by 3.0% in the 1st quarter. Invesco Ltd. now owns 159,705 shares of the company’s stock valued at $12,688,000 after purchasing an additional 4,604 shares in the last quarter. 52.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. DA Davidson raised their price target on shares of USANA Health Sciences from $49.00 to $52.50 and gave the company a “neutral” rating in a research note on Monday, February 13th. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 16th.

USANA Health Sciences Price Performance

Shares of NYSE USNA opened at $61.83 on Thursday. The company has a 50 day simple moving average of $58.00 and a 200 day simple moving average of $57.75. The firm has a market cap of $1.19 billion, a PE ratio of 17.22 and a beta of 0.73. USANA Health Sciences, Inc. has a 1 year low of $48.61 and a 1 year high of $90.29.

USANA Health Sciences (NYSE:USNA – Get Rating) last released its quarterly earnings results on Tuesday, February 7th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.31. USANA Health Sciences had a net margin of 6.94% and a return on equity of 16.92%. The firm had revenue of $227.96 million during the quarter. During the same quarter in the previous year, the business posted $1.03 EPS. As a group, research analysts anticipate that USANA Health Sciences, Inc. will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other USANA Health Sciences news, CEO Kevin Guest sold 13,288 shares of the firm’s stock in a transaction that occurred on Wednesday, February 22nd. The shares were sold at an average price of $60.28, for a total transaction of $801,000.64. Following the completion of the transaction, the chief executive officer now owns 9,355 shares in the company, valued at approximately $563,919.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Daniel A. Macuga sold 1,474 shares of USANA Health Sciences stock in a transaction on Monday, December 5th. The shares were sold at an average price of $53.92, for a total value of $79,478.08. Following the completion of the sale, the insider now owns 2,234 shares in the company, valued at approximately $120,457.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin Guest sold 13,288 shares of USANA Health Sciences stock in a transaction on Wednesday, February 22nd. The shares were sold at an average price of $60.28, for a total transaction of $801,000.64. Following the completion of the sale, the chief executive officer now owns 9,355 shares of the company’s stock, valued at approximately $563,919.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,809 shares of company stock worth $1,251,393. 0.36% of the stock is currently owned by insiders.

About USANA Health Sciences

(Get Rating)

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm’s brands include Procosa and MagneCal D. The company was founded by Myron W.